Items Tagged ‘News’

May 20, 2019

Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia

By

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable results. (1) About chronic lymphocytic leukemia CLL is the most common type of leukemia in adults. (2) with an average age […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Genetics, germline mutations, Hereditary Caner Test, hereditary risk, Leukemia, myRisk, News, Prostate Cancer


May 7, 2019

Zytig Treatment Prolongs Survival in Advanced Prostate Cancer

By

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About Zytig Zytiga is an oral targeted agent that blocks the production of androgens (male hormones such as testosterone) not only by the testes, but […]

View full entry

Tags: News, Prostate Cancer


May 7, 2019

FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation

By

On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. Approval was […]

View full entry

Tags: Leukemia, News


May 6, 2019

Subcutaneous Herceptin Effective Option for Women With HER2-positive Breast Cancer

By

One year of IV Herceptin (trastuzumab) is the standard of care for women with HER2-positive early stage breast cancer (ESBC). Doctors from Germany have confirmed that Herceptin can safely be administered subcutaneously without compromising effectiveness – increasing patient convenience. Dr. Jackisch M.D. and colleagues reported the results of an open-label, multi-center, international clinical trial to […]

View full entry

Tags: Breast Cancer, News


May 3, 2019

Ice Chips May Be The Easiset Way to Reduce Mucositis From Cancer Treatment

By

A new study in the April 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network reports that oral cryotherapy reduce mucositis related side effects. Ice chips or “cryotherapy” has long been used to reduce the intensity of mouth sores called mucositis that occur following treatment with stem cell transplant and certain chemotherapy drugs. This current study enrolled 50 […]

View full entry

Tags: News


May 1, 2019

ASCO Guideline: Oxaliplatin Adjuvant Therapy for Stage III Colon Cancer May Be Reduced in Select Patients

By

The American Society of Clinical Oncology (ASCO) has released a new guideline that states that patients with clinically low-risk stage III colon cancer should have the option of receiving 3 months of adjuvant oxaliplatin-based chemotherapy. For patients at a high risk of recurrence (T4 and/or N2), adjuvant chemotherapy should be offered for a duration of […]

View full entry

Tags: Colon Cancer, News


April 30, 2019

37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer

By

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer (ESBC).(1) In the United States “dose dense” chemotherapy is considered standard of care for the treatment […]

View full entry

Tags: Breast Cancer, News


April 16, 2019

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

By

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Today, […]

View full entry

Tags: Bladder Cancer, News


April 11, 2019

Most women can get mammograms every other year starting at age 50

By

Women who are not at high risk for breast cancer can wait to start getting mammograms until age 50 and be screened every other year, according to new guidelines from the American College of Physicians. Women at high risk for breast cancer are those with a family history of breast cancer, previous cancer scares, dense […]

View full entry

Tags: News


April 8, 2019

Dose Intense Chemotherapy Improves Survival When Used For Treatment of Early Stage Breast Cancer

By

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer. The analyses was performed by British physicians in the Early Breast Cancer Trialists Collaborative Group who evaluated 37,000 women who participated in 26 clinical trials […]

View full entry

Tags: Breast Cancer, News


April 4, 2019

CD40 Combination Therapy Can Shrink Pancreatic Tumors

By

A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients – 20 out of 24 as of an interim analysis of the phase 1b trial data. The early findings provide hope that this strategy involving a CD40 antibody, a checkpoint inhibitor, and standard-of-care chemotherapy could […]

View full entry

Tags: News, Pancreatic Cancer


March 28, 2019

GARNET Study Suggets Dostarlimab Promising for Uterine/Endometrial Cancer

By

An early phase clinical trial evaluating dostarlimab in women with recurrent or advanced endometrial cancer appears promising.  These data were presented at the 2019 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Honolulu, Hawaii. Endometrial cancer (EC) is the most common gynaecologic malignancy in the U.S. but there are limited treatment options […]

View full entry

Tags: News, Uterine Cancer


March 26, 2019

NCCN Updates Ovarian Cancer Guidelines

By

The NCCN has recently updated its ovarian cancer treatment guidelines and make the following significant changes. All patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer should have a genetic risk evaluation and BRCA1/2 testing performed. Maintenance Therapy: Lynparza (olaparib) was added as a maintenance therapy option after complete or partial clinical remission […]

View full entry

Tags: News, Ovarian Cancer


March 20, 2019

Prophylactic Cranial Irradiation Improves Disease-Free Survival and Brain Metastasis Rates for Locally Advanced Non-Small Cell Lung Cancer

By

PHILADELPHIA, PA– Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer […]

View full entry

Tags: Lung Cancer - Non-Small Cell, News


March 18, 2019

Lynparza Delays Progression of BRCA-mutated Metastatic Pancreatic Cancer

By

Lynparza (olaparib) improves progression-free survival (PFS) when used to treat BRCA-mutated pancreatic cancer and appears to represent a new treatment option for this hard to treat cancer. (1-4) About BRCA Mutated Pancreatic Cancer Pancreatic cancer has the worst survival rate of the most common cancers and less than seven percent of patients survive more than […]

View full entry

Tags: News, Pancreatic Cancer